Mode of administration A factor in biologic drug costs
Of
drugs in late stages of development, 73 percent will
need to be administered by a healthcare provider, with
the bulk of those being administered intravenously.
Sixty percent of drugs in late stages of compliance is
often poor, resulting in additional costs to get the
patient back on track. In-office administration of bio-
pharmaceuticals reduce...
Url:
http://www.biotechnologyhealthcare.com/journal/fulltext/1/4/BH0104064.pdf
Cached View
CMS Introduces New Payment Rates for Drugs and Their Adminis
....
To avert
that, CMS is working with carriers
and CMS regional offices.
HELP FOR PRIVATE PAYERS
At the than 120 percent higher than in
2003. In addition, physicians will
have more opportunities to bill for
administration services (see table).
These provisions offset the loss of
generous “transition payments”
made last year to physicians in ment is....
Url:
http://www.biotechnologyhealthcare.com/journal/fulltext/2/1/BH0201017.pdf
Cached View
Biotechnology Healthcare - Daily News
Biotechnology Healthcare - Daily News A GUIDE FOR DECISION MAKERS ON THE BIOTECHNOLOGY REVOLUTION MORE MEDIMEDIA SITES: → Managed Care Journal → P&T Community percent). Monday, Jun 18 Canfosfamide Trials Changed to Partial Hold Status Telik announced that the U.S. Food and Drug Administration has converted the recently announced full clinical hold...
Url:
http://www.biotechnologyhealthcare.com/daily/
Cached View
Biotechnology Healthcare Journal
June 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare Journal Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints September 2004 Features Clinical How ...
Url:
http://www.biotechnologyhealthcare.com/journal/journalview.cfm?volume=1&issu
...
Cached View
Biotechnology Healthcare Journal
Biotechnology Healthcare Journal A GUIDE FOR DECISION MAKERS ON THE BIOTECHNOLOGY REVOLUTION MORE MEDIMEDIA SITES: → Managed Care Journal → P&T Community → CE June 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare Jo...
Url:
http://www.biotechnologyhealthcare.com/journal/journalview.cfm?volume=1&issu
...
Cached View
Biotechnology Healthcare Journal
Biotechnology Healthcare Journal A GUIDE FOR DECISION MAKERS ON THE BIOTECHNOLOGY REVOLUTION MORE MEDIMEDIA SITES: → Managed Care Journal → P&T Community → CE June 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare Jo...
Url:
http://www.biotechnologyhealthcare.com/journal/journalview.cfm?volume=3&issu
...
Cached View
Biotechnology Healthcare Journal
Biotechnology Healthcare Journal A GUIDE FOR DECISION MAKERS ON THE BIOTECHNOLOGY REVOLUTION MORE MEDIMEDIA SITES: → Managed Care Journal → P&T Community → CE June 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare Jo...
Url:
http://www.biotechnologyhealthcare.com/journal/journalview.cfm?volume=2&issu
...
Cached View
Biotechnology Healthcare Journal
Biotechnology Healthcare Journal A GUIDE FOR DECISION MAKERS ON THE BIOTECHNOLOGY REVOLUTION MORE MEDIMEDIA SITES: → Managed Care Journal → P&T Community → CE June 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare Jo...
Url:
http://www.biotechnologyhealthcare.com/journal/journalview.cfm?volume=2&issu
...
Cached View
Biotechnology Healthcare - Daily News
Biotechnology Healthcare - Daily News A GUIDE FOR DECISION MAKERS ON THE BIOTECHNOLOGY REVOLUTION MORE MEDIMEDIA SITES: → Managed Care Journal → P&T Community Over three million prescriptions have been written in the U.S. since being approved by the Food and Drug Administration (FDA) in 2005. For more information, visit www.byetta.com. About Byett...
Url:
http://www.biotechnologyhealthcare.com/Daily/DailyDetail.cfm?chosen=1109
Cached View
Biotechnology Healthcare - Daily News
Biotechnology Healthcare - Daily News A GUIDE FOR DECISION MAKERS ON THE BIOTECHNOLOGY REVOLUTION MORE MEDIMEDIA SITES: → Managed Care Journal → P&T Community States for combination HIV therapy. Viread received approval as an anti-HIV medication from the U.S. Food and Drug Administration (FDA) in October 2001 and from the European Commission in Fe...
Url:
http://www.biotechnologyhealthcare.com/Daily/DailyDetail.cfm?chosen=1108
Cached View
Intravenous Drugs May Be Losing Favor
According to The Zitter Group’s Fall 2005
Managed Care Injectables Index, the use of carve-out of the index, below, outlines some payer attitudes that may underpin this trend.
Patient management issues, the difficulty of negotiating administration fees with physicians, ASP-based
reimbursements, and the effect of Medicare Part D also may help to.....
Url:
http://www.biotechnologyhealthcare.com/journal/fulltext/3/1/BH0301064.pdf
Cached View
Biotech Cheers 4 More Years, But Familiar Struggles Still Ah
....
With Bush in sought to limit research.
On the federal level, Bush’s track
record on price controls and re-
importation — his administration
has steadfastly opposed both —
was enough to leave biotech leaders
feeling bullish about the near-term.
But with drug prices making the elections. But the old
issues of reimportation
and potential price...
Url:
http://www.biotechnologyhealthcare.com/journal/fulltext/1/6/BH0106012.pdf
Cached View
Approvals, FDA Actions, Clinical Trials
AUGUST 2005 · BIOTECHNOLOGY HEALTHCARE 13
DRUGTRACK
CLINICAL TRIALS/
DRUG DEVELOPMENT
Cetuximab (Erbitux), in combi-
nation with radiation therapy,
prevented the spread of head Remicade) for treat-
ment of ulcerative colitis has been
granted priority review by the U.S.
Food and Drug Administration.
The sBLA is based on two phase 3
trials in patien...
Url:
http://www.biotechnologyhealthcare.com/journal/fulltext/2/4/BH0204013.pdf
Cached View
Specialty Drug Costs Continue To Rise; Employees Hit With Hi
....
18 BIOTECHNOLOGY HEALTHCARE · DECEMBER 2005
BIOTECH BUSINESS
“We have had a 5 percent de-
cline in the number of workers
covered GUIDE AND TREND
REPORT 2004; IMS HEALTH 2005, WALL STREET EQUITY RESEARCH 2004, CENTERS
FOR MEDICARE AND MEDICAID NATIONAL HEALTHCARE EXPENDITURE PROJECTION
2003–2013
DECEMBER 2005 · BIOTECHNOLOGY HEALTHCARE 19
adminis...
Url:
http://www.biotechnologyhealthcare.com/journal/fulltext/2/6/BH0206018.pdf
Cached View
Marking the Progress of Genetic Testing
APRIL 2005 · BIOTECHNOLOGY HEALTHCARE 15
DRUGS AND DIAGNOSTICS
lesions could be excised, and the
cancer risk reduced.
When no preventive strategies
or cures exist scheduled for annual colonos-
copies, during which precancerous
Marking the Progress of Genetic Testing
BY BOB
CARLSON
16 BIOTECHNOLOGY HEALTHCARE · APRIL 2005
DRUGS AND DIAGNOSTICS
The ...
Url:
http://www.biotechnologyhealthcare.com/journal/fulltext/2/2/BH0202015.pdf
Cached View
Biotech Pipeline Set For Future Sales Growth
S. Food and Drug
Administration review for market approval. Nearly 50
percent of all new medicines approved by the FDA in
2003 brimming with drugs targeting central
nervous system and cardiovascular disorders
— Amanda Brower
Biotech Pipeline Set
For Future Sales Growth
64 BIOTECHNOLOGY HEALTHCARE · JULY/AUGUST 2004
SOURCE: RESURGENCE: GLOBAL...
Url:
http://www.biotechnologyhealthcare.com/journal/fulltext/1/3/BH0103064.pdf
Cached View
Biotech developing 324 new products
150 diseases. These poten-
tial new drugs are either under review for approval
by the U.S. Food and Drug Administration or in
human clinical trials.
A closer look finds 154 investigational cancer drugs,
accounting for 48 percent of FDA approval will supplement the
108 biotechnology drugs already on the market.
— Amanda Brower
Biotech developing 32...
Url:
http://www.biotechnologyhealthcare.com/journal/fulltext/1/6/BH0106064.pdf
Cached View
Number of Monoclonal Antibodies on Market Nearly Doubles by
....
Based on an
analysis of past approval rates, Tufts projects that by
2008, the U.S. Food and Drug Administration is likely
to approve 11 of the current mAb products in the
pipeline.* In effect the bulk of mAb sales — $7.2 billion, or 43
percent of the total mAb market. — Amanda Brower
64 BIOTECHNOLOGY HEALTHCARE · JUNE 2005
SOURCES: PROTEIN...
Url:
http://www.biotechnologyhealthcare.com/journal/fulltext/2/3/BH0203064.pdf
Cached View
Base Hits
S.
Food and Drug Administration has
approved a number of pharmaco-
genomic products. This gives us con-
fidence in the prospect of Global
Technology Centre and Health Re-
search Institute of PriceWaterhouse-
Coopers. February 2005.
DAVID B. NASH,
MD, MBA
EDITORIAL
6 BIOTECHNOLOGY HEALTHCARE...
Url:
http://www.biotechnologyhealthcare.com/journal/fulltext/2/5/BH0205006.pdf
Cached View
Approvals, FDA Actions, Clinical Trials
10 BIOTECHNOLOGY HEALTHCARE · OCTOBER 2005
DRUGTRACK
mental therapy for non-small cell
lung cancer (NSCLC) — seeking ap-
proval for use in women supplement) (Influenza Pasteur injection
virus vaccine)
Aug. 18, 2005 FluMist (In- MedImmune 2005–2006 U.S. formulation Nasal 0.5 ml
(supplement) fluenza virus administration
vaccine, live)
Aug. 31, 2005 ...
Url:
http://www.biotechnologyhealthcare.com/journal/fulltext/2/5/BH0205010.pdf
Cached View